Lataa...
Safety Exposure‐Response Analysis for Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV‐Infected Subjects
The combination regimen of daclatasvir, asunaprevir, and beclabuvir has been developed for the treatment of hepatitis C virus infection. The objectives of this analysis were to characterize the relationship between the exposures of the daclatasvir, asunaprevir, and beclabuvir regimen and liver‐relat...
Tallennettuna:
| Julkaisussa: | J Clin Pharmacol |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley and Sons Inc.
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6590348/ https://ncbi.nlm.nih.gov/pubmed/30566237 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1347 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|